PFAS And Pathogen Regulations Will Support Long Term Upside Potential

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

20 Jan 26

Updated

01 Aug 26

Views

Not Invested

Shared on 01 Aug 26

Fair value Decreased 14%

NEPH: Index Additions And Water Filtration Leadership Will Support Future Upside

Nephros lands in major Russell indexes while management leans on its balance sheet to hire and look for deals to drive the next leg of growth. But expectations cool as analysts cut what they think the business is worth and say they want to see sales momentum strengthen and profits hold up.

0 views

Fair Value vs Share Price

US$6

vs US$3.3943.5% undervalued

14.9%

Revenue growth

6.1%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Nephros

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with reasonable growth potential.

Market capUS$38.0m

PB3.4x

Estimated Growth12.5%

Dividend YieldN/A

Full analysis

CEO & management

Robert Banks

CEO

3.5yrs

CEO Tenure

A commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States.